Page 6 - Natco Pharma

Multiple growth pills should keep Natco Pharma's revenue charts healthy

The Natco Pharma stock was up six per cent in two trading sessions on expectations of a strong March quarter performance and near-term triggers such as approval for generics of multiple sclerosis drug Copaxone. For the March quarter, while the pharma sector is expected to report single-digit revenue and flat net profit growth, Natco Pharma could witness a growth of 24 per cent in revenues and 117 per cent rise in its bottom line. The better performance is due to the launch of the generic version of influenza drug Tamiflu in December 2016 in the US. The drug, marketed by its US partner Alvogen, has sales of about $400 million. In addition to a strong March quarter performance, the next trigger is the approval for generics of Copaxone (40 mg strength) which has annual sales of $3.3 billion. The verdict on a patent case is due in May 2017 and a favourable outcome of this could mean a ~400-500-crore revenue opportunity, according to analysts. Natco, along with its US partner Mylan, ...

Natco Pharma gets USFDA approval for leukemia drug

Natco plans to launch this on November 1, 2019 through its partner Breckenridge Pharmaceutical Inc

Natco Pharma gains on USFDA nod for generic Bendamustine HCL powder

The stock moved higher by 6% to Rs 632 on the BSE in intra-day trade

Natco gets USFDA nod for anti-sleep tablets

Armodafinil treats daytime sleepiness linked to sleep apnea, narcolepsy and shift work disorder; generic equivalent in the US had sales of $480 mn in 2015

Natco plans to double drug filings next year

The company aims to file six abbreviated new drug applications (ANDA) during current financial year

Maylan gets favourable ruling on one more patent of Copaxone

The company, which is Natco Pharma's marketing partner, hopes to translate this potential para-4 filing into a product launch after clearing legal hurdles

Natco Pharma upbeat over US Patent Office's ruling on two of Copaxone patents

In August 2014, Mylan had filed the abbreviated new drug application for multiple sclerosis drug Copaxone 40 mg/ml with the US FDA

Natco Pharma zooms on EIR for Chennai facility

The stock moved higher to its fresh lifetime high of Rs 703, up 7% on the National Stock Exchange.

Natco gets EIR from USFDA for Kothur facility

Company's shares were trading 1.10% higher at Rs 641 on BSE in afternoon session

Natco Pharma Q1 net profit jumps almost 70% to Rs 48 crore

Formulations' share in total income of the company rose to 87% in the quarter, compared to 76.49% in the corresponding quarter last fiscal.

Natco Pharma Q1 net up 69.7 pc to Rs 47.65 crore

Shares of Natco Pharma ended 1.65 per cent down at Rs 625.80 on BSE

Natco Pharma gets final approval for Tamiflu capsules in the US

The company filed ANDA, containing a para IV certification, claiming first to file status in 2011 and was granted tentative approval by USFDA in March 2014

Natco Pharma shares soar over 7% on nod for Tamiflu drugs

At NSE, it moved up by 6.89 per cent to touch its 52-week high of Rs 650

Natco Pharma hits 52-week high on USFDA nod for generic Tamiflu

The stock rallied 7% to Rs 650 also its 52-week high on the National Stock Exchange in early morning trade.

Natco Pharma gains on USFDA nod for generic Glycopyrrolate tablets

The stock was trading higher by 4% to Rs 552, extending its Wednesday's 6% rally on the BSE

Natco Pharma gains on tentative nod from USFDA for cancer drug

The stock up 9% to Rs 523 after the company said that its marketing partner, Mylan Inc., has received a US regulator tentative nod Sorafenib, the generic version of Nexavar.

Natco Pharma gains on sale of non-core business in US

The board approved the sale of Save Mart Pharmacy Stores located in USA which is non-core business

US regulator looms over Natco prospects

Company says no impact on product pipeline but Street awaits more clarity

Natco Pharma slips on USFDA observations

The stock slipped 11% to Rs 417 on the BSE in early morning trade.

USFDA observations on 2 units not to impact products: Natco

Natco Pharma Ltd has already sent response and compliance report for these observations